Takatsuki, Japan

Takuya Matsui

USPTO Granted Patents = 2 



Average Co-Inventor Count = 13.3

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2007-2012

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Takuya Matsui: Innovator in Pharmaceutical Compounds

Introduction

Takuya Matsui is a notable inventor based in Takatsuki, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications. With a total of 2 patents, Matsui's work focuses on innovative solutions for various medical conditions.

Latest Patents

Matsui's latest patents include a triazolopyridine compound that acts as a prolyl hydroxylase inhibitor and an erythropoietin production-inducing agent. This invention provides a compound that demonstrates a prolyl hydroxylase inhibitory action and an ability to induce erythropoietin production. The compound is useful as a prophylactic or therapeutic agent for diseases caused by decreased erythropoietin production. Another patent involves fused bicyclic nitrogen-containing heterocycles, which are compounds and pharmaceutical compositions aimed at treating metabolic and cell proliferative diseases. These compounds modulate the activity of proteins involved in lipid metabolism and cell proliferation.

Career Highlights

Matsui is currently employed at Japan Tobacco Inc., where he continues to innovate and develop new pharmaceutical solutions. His work has garnered attention for its potential impact on health and medicine.

Collaborations

Matsui has collaborated with notable colleagues, including Brian M. Fox and Noboru Furukawa, contributing to a dynamic research environment that fosters innovation.

Conclusion

Takuya Matsui's contributions to pharmaceutical inventions highlight his role as a key innovator in the industry. His patents reflect a commitment to addressing significant health challenges through scientific advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…